Clinical Trial Update: Clinical Trial Evaluating the Activity of Zanidatamab for the Treatment of Patients With Solid Tumors With an Alteration of the HER2 Gene. [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating zanidatamab for solid tumors with HER2 gene alterations across multiple indications and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Endometrial Cancer
• Head and Neck Cancer
• Non-small Cell Lung Cancer
• Sarcoma

Drugs mentioned

• Zanidatamab

Snippet

Sponsor: UNICANCER | Conditions: Non-Small Cell Lung Cancer, Sarcoma | Phase 2 | Status: RECRUITING